Onderneming Endonovo Therapeutics, Inc. Other OTC
Aandelen
ENDV
US29272H3003
Biotechnologie & Medisch Onderzoek
Vakgebied
Verkoop per activiteit
USD in miljoen | 2022 | Gewicht | 2023 | Gewicht | Delta |
---|---|---|---|---|---|
Royalty/Licensing, Net
90,2
%
| 0 | 83,9 % | 0 | 90,2 % | +11,35% |
Direct Sales - Plastic Surgeons, Gross
9,8
%
| 0 | 16,1 % | 0 | 9,8 % | -36,86% |
Verkoop per regio
USD in miljoen | 2022 | Gewicht | 2023 | Gewicht | Delta |
---|---|---|---|---|---|
United States
100,0
%
| 0 | 100,0 % | 0 | 100,0 % | +3,61% |
Managers
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Alan Collier
CEO | Chief Executive Officer | 59 | 01-03-12 |
Don Calabria
COO | Chief Operating Officer | 53 | - |
Steven Barnes
IRC | Investor Relations Contact | - | 01-05-14 |
Corporate Officer/Principal | 68 | 01-03-22 | |
David Clark
SAM | Sales & Marketing | - | 03-05-19 |
Ira Weisberg
PRN | Corporate Officer/Principal | 75 | 30-11-22 |
Besturend
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Alan Collier
CEO | Chief Executive Officer | 59 | 01-03-12 |
Aandelenklasse
Stemming | Aantal | Vrij verhandelbaar | Bedrijfseigen aandelen | Drijvend Totaal | |
---|---|---|---|---|---|
Aandeel A | 0 | 600 | 0 | 0 | 77,47 % |
Aandeel B | 1 | 349 394 357 | 270 662 701 ( 77,47 %) | 0 | |
Aandeel C | 0 | 25 000 | 0 | 0 |
Bedrijfsgegevens
Endonovo Therapeutics, Inc.
6320 Canoga Avenue 15th Floor
91367, Woodland Hills
+800 489 4774
http://www.endonovo.comSector
Verkoop per activiteit
Vaira. 1 jan. | Kapi. | |
---|---|---|
+7,52% | 113 mld. | |
+11,38% | 106 mld. | |
-12,64% | 22,22 mld. | |
+0,20% | 22,27 mld. | |
-3,57% | 19,43 mld. | |
-37,85% | 17,87 mld. | |
-8,58% | 17,24 mld. | |
+37,41% | 12,52 mld. | |
-23,95% | 8,34 mld. |